Sinotherapeutics Inc. A
Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company's products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extende… Read more
Sinotherapeutics Inc. A (688247) - Total Liabilities
Latest total liabilities as of June 2025: CN¥142.10 Million CNY
Based on the latest financial reports, Sinotherapeutics Inc. A (688247) has total liabilities worth CN¥142.10 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sinotherapeutics Inc. A - Total Liabilities Trend (2020–2024)
This chart illustrates how Sinotherapeutics Inc. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sinotherapeutics Inc. A Competitors by Total Liabilities
The table below lists competitors of Sinotherapeutics Inc. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Lilang Limited
F:5LX
|
Germany | €2.43 Billion |
|
QuickLogic Corporation
NASDAQ:QUIK
|
USA | $22.34 Million |
|
Wuxi Xinan Technology Co. Ltd. A
SHE:301170
|
China | CN¥170.18 Million |
|
Boyaa Interactive International Limited
F:1BY
|
Germany | €562.55 Million |
|
Epigral Ltd.
NSE:EPIGRAL
|
India | ₹11.35 Billion |
|
Thirumalai Chemicals Limited
NSE:TIRUMALCHM
|
India | ₹28.12 Billion |
|
Sang-A Frontec Co.Ltd
KQ:089980
|
Korea | ₩171.13 Billion |
|
Selvita S.A.
WAR:SLV
|
Poland | zł294.51 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Sinotherapeutics Inc. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sinotherapeutics Inc. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sinotherapeutics Inc. A (2020–2024)
The table below shows the annual total liabilities of Sinotherapeutics Inc. A from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥180.30 Million | +19.12% |
| 2023-12-31 | CN¥151.36 Million | -2.38% |
| 2022-12-31 | CN¥155.05 Million | -3.47% |
| 2021-12-31 | CN¥160.62 Million | -11.14% |
| 2020-12-31 | CN¥180.76 Million | -- |